Table 2.
Effect of different oligoadenylate synthetase (OAS) genotypes on response rate, liver activity and liver fibrosis
| Factor | OAS | P‐value* | ||
|---|---|---|---|---|
| AA | AG | GG | ||
| n = 9 | n = 29 | n = 32 | ||
| n (%) | n (%) | n (%) | ||
| Fibrosis | ||||
| F1 | 1 (11.1) | 11 (37.9) | 18 (56.3) | |
| F2–F4 | 8 (88.9) | 18 (62.1) | 14 (43.7) | 0.05 |
| Activity | ||||
| A1 | 4 (44.4) | 19 (65.5) | 24 (75.0) | |
| A2–A3 | 5 (55.6) | 10 (34.5) | 8 (25.0) | 0.220 |
| HCV | ||||
| Responders | 1 (11.1) | 11 (37.9) | 19 (59.4) | |
| Non responders | 9 (88.9) | 18 (62.1) | 13 (40.6) | 0.007 |
*
P‐values ≤ 0.05 are considered significant.
The effect of OAS single nucleotide polymorphism (SNP) on liver fibrosis, liver activity and response rate to therapy was statistically analyzed. HCV, hepatitis C virus.